OBJECTIVE: The aim of this study is to determine when during hematopoiesis Siglec-8 gets expressed, whether it is expressed on hematologic malignancies, and if there are other non-human species that express Siglec-8. METHODS: Siglec-8 mRNA and cell surface expression was monitored during in vitro maturation of human eosinophils and mast cells. Flow cytometry was performed on human blood and bone marrow samples, and on blood samples from dogs, baboons, and rhesus and cynomolgus monkeys. RESULTS: Siglec-8 is a late maturation marker. It is detectable on eosinophils and basophils from subjects with chronic eosinophilic leukemia, chronic myelogenous leukemia, and on malignant and non-malignant bone marrow mast cells, as well as the HMC-1.2 cell line. None of the Siglec-8 monoclonal antibodies tested recognized leukocytes from dogs, baboons, and rhesus and cynomolgus monkeys. CONCLUSIONS: Siglec-8-based therapies should not target immature human leukocytes but should recognize mature and malignant eosinophils, mast cells, and basophils. So far, there is no suitable species for preclinical testing of Siglec-8 monoclonal antibodies.
OBJECTIVE: The aim of this study is to determine when during hematopoiesis Siglec-8 gets expressed, whether it is expressed on hematologic malignancies, and if there are other non-human species that express Siglec-8. METHODS:Siglec-8 mRNA and cell surface expression was monitored during in vitro maturation of human eosinophils and mast cells. Flow cytometry was performed on human blood and bone marrow samples, and on blood samples from dogs, baboons, and rhesus and cynomolgus monkeys. RESULTS:Siglec-8 is a late maturation marker. It is detectable on eosinophils and basophils from subjects with chronic eosinophilic leukemia, chronic myelogenous leukemia, and on malignant and non-malignant bone marrow mast cells, as well as the HMC-1.2 cell line. None of the Siglec-8 monoclonal antibodies tested recognized leukocytes from dogs, baboons, and rhesus and cynomolgus monkeys. CONCLUSIONS:Siglec-8-based therapies should not target immature human leukocytes but should recognize mature and malignant eosinophils, mast cells, and basophils. So far, there is no suitable species for preclinical testing of Siglec-8 monoclonal antibodies.
Authors: N Zimmermann; M L McBride; Y Yamada; S A Hudson; C Jones; K D Cromie; P R Crocker; M E Rothenberg; B S Bochner Journal: Allergy Date: 2008-09 Impact factor: 13.146
Authors: Kimberly D Dyer; Jennifer M Moser; Meggan Czapiga; Steven J Siegel; Caroline M Percopo; Helene F Rosenberg Journal: J Immunol Date: 2008-09-15 Impact factor: 5.422
Authors: Hidenori Yokoi; Oksoon H Choi; Walter Hubbard; Hyun-Sil Lee; Brendan J Canning; Hyun H Lee; Seung-Duk Ryu; Stephan von Gunten; Carol A Bickel; Sherry A Hudson; Donald W Macglashan; Bruce S Bochner Journal: J Allergy Clin Immunol Date: 2007-11-26 Impact factor: 10.793
Authors: Matthias Mayerhofer; Karoline V Gleixner; Andrea Hoelbl; Stefan Florian; Gregor Hoermann; Karl J Aichberger; Martin Bilban; Harald Esterbauer; Maria-Theresa Krauth; Wolfgang R Sperr; Jack B Longley; Robert Kralovics; Richard Moriggl; Jacques Zappulla; Roland S Liblau; Ilse Schwarzinger; Veronika Sexl; Christian Sillaber; Peter Valent Journal: J Immunol Date: 2008-04-15 Impact factor: 5.422
Authors: Sandhya R Panch; Michael E Bozik; Thomas Brown; Michelle Makiya; Calman Prussin; Donald G Archibald; Gregory T Hebrank; Mary Sullivan; Xiaoping Sun; Lauren Wetzler; JeanAnne Ware; Michael P Fay; Cynthia E Dunbar; Steven I Dworetzky; Paneez Khoury; Irina Maric; Amy D Klion Journal: Blood Date: 2018-05-08 Impact factor: 22.113
Authors: Cheng Peng; Evelien R Van Meel; Andres Cardenas; Sheryl L Rifas-Shiman; Abhijeet R Sonawane; Kimberly R Glass; Diane R Gold; Thomas A Platts-Mills; Xihong Lin; Emily Oken; Marie-France Hivert; Andrea A Baccarelli; Nicolette W De Jong; Janine F Felix; Vincent W Jaddoe; Liesbeth Duijts; Augusto A Litonjua; Dawn L DeMeo Journal: Epigenetics Date: 2019-03-28 Impact factor: 4.528
Authors: Jeremy A O'Sullivan; Daniela J Carroll; Yun Cao; Adriano N Salicru; Bruce S Bochner Journal: J Allergy Clin Immunol Date: 2017-07-20 Impact factor: 10.793
Authors: Bradford A Youngblood; Emily C Brock; John Leung; Rustom Falahati; Bruce S Bochner; Henrik S Rasmussen; Kathryn Peterson; Christopher Bebbington; Nenad Tomasevic Journal: JCI Insight Date: 2019-10-03
Authors: John W Steinke; Lixia Liu; Phillip Huyett; Julie Negri; Spencer C Payne; Larry Borish Journal: J Allergy Clin Immunol Date: 2013-06-24 Impact factor: 10.793
Authors: Peter Valent; Gerald J Gleich; Andreas Reiter; Florence Roufosse; Peter F Weller; Andrzej Hellmann; Georgia Metzgeroth; Kristin M Leiferman; Michel Arock; Karl Sotlar; Joseph H Butterfield; Sabine Cerny-Reiterer; Matthias Mayerhofer; Peter Vandenberghe; Torsten Haferlach; Bruce S Bochner; Jason Gotlib; Hans-Peter Horny; Hans-Uwe Simon; Amy D Klion Journal: Expert Rev Hematol Date: 2012-04 Impact factor: 2.929
Authors: Bradford A Youngblood; Emily C Brock; John Leung; Rustom Falahati; Paul J Bryce; Jessica Bright; Jason Williams; Leonard D Shultz; Dale L Greiner; Michael A Brehm; Christopher Bebbington; Nenad Tomasevic Journal: Int Arch Allergy Immunol Date: 2019-08-09 Impact factor: 2.749
Authors: Paul J Bryce; Rustom Falahati; Laurie L Kenney; John Leung; Christopher Bebbington; Nenad Tomasevic; Rebecca A Krier; Chia-Lin Hsu; Leonard D Shultz; Dale L Greiner; Michael A Brehm Journal: J Allergy Clin Immunol Date: 2016-04-06 Impact factor: 10.793